Impact of Glycopyrrolate on Carotid Angioplasty and Stenting
- Conditions
- Carotid angioplasty and stenting for carotid stenosisCardiovascular - Other cardiovascular diseases
- Registration Number
- ACTRN12606000358549
- Lead Sponsor
- Dr Crispin Wan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
All patients for carotid angioplasty and stenting.
Exclusion Criteria
Inability to consent, patient refusal, allergy to glycopyrrolate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in intra-operative bradycardia and/or hypotension[Intra-operative]
- Secondary Outcome Measures
Name Time Method Reduction in post-operative cardiovascular and neurological morbidity and mortality.[Post-operative till discharge (usually 3 days).]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does glycopyrrolate's anticholinergic action modulate vagal tone during carotid angioplasty and stenting in ACTRN12606000358549?
What is the comparative efficacy of glycopyrrolate versus atropine in preventing bradycardia during carotid stenting per ACTRN12606000358549?
Which biomarkers correlate with glycopyrrolate response in carotid stenosis patients undergoing angioplasty in ACTRN12606000358549?
What adverse events are associated with glycopyrrolate use in carotid angioplasty and how are they managed in ACTRN12606000358549?
How does glycopyrrolate compare to other anticholinergic agents in preventing hypotension during carotid procedures in ACTRN12606000358549?